26
A P R I L 2021 ME S S E NG E R
acknowledgment of the risks mentioned above and the absence of evidence on the use of COVID-19 vaccine in these populations. Additional resources: • COVID-19 Scientific Advisory Group Rapid Evidence Report. • Advisory Committee on Immunization Practices (ACIP) interim recommendations for the use of PfizerBioNTech and Moderna COVID-19 vaccines. Does Alberta Health track adverse events following immunization? Alberta has a central reporting system for reporting adverse reactions following immunization (AEFIs) that allows Alberta Health Services and Alberta Health to rapidly assess any potential risks and take immediate action when necessary. Active surveillance is another component of tracking AEFIs that involves proactively collecting information about adverse events from vaccine recipients. Albertans who receive COVID-19 vaccine may be asked to take part in a surveillance study that is looking to determine how often adverse events occur after receiving a COVID-19 vaccine. For more information visit https://canvas-covid.ca/. Alberta Health will not hesitate to take action if any safety concerns are identified. Emerging information will be communicated promptly to Canadians and Albertans if needed, such as new information on risks, or changes to who can be immunized. The total number of AEFIs reported to-date can be found here: https://www.alberta.ca/covid19-vaccine.aspx. What ingredients are in the vaccine? The two vaccines available for use contain ingredients that help the vaccine work in the body and protect the vaccine while frozen. The vaccines do not contain antibiotics or preservatives. One non-medicinal ingredient in both the Moderna and Pfizer BioNTech vaccines may cause a hypersensitivity reaction. This ingredient is polyethylene glycol (PEG). This ingredient is also found in cosmetics, cough syrup, skin products and some food and drinks. When you are being immunized or offering immunization, potential allergic reactions will be discussed. Moderna Pfizer BioNTech Lipid nanoparticles (these help the mRNA enter the cell): • PEG2000-DMG LSM-102, 1,2-dimyristoyl-rac- glycero-3methoxypolyethyleneglycol • 1,2-distearoyl-sn-glycero-3phosphocholine [DSPC]) • Cholesterol • Lipid SM-102 pH stabilizers (help maintain the PH of the vaccine) • acetic acid Lipid nanoparticles (these help the mRNA enter the cell): • ALC-0315 = (4-hydroxybutyl) azanediyl)bis(hexane- 6,1-diyl)bis(2hexyldecanoate)
• ALC-0159 = 2-[(polyethylene glycol)- • 2000]-N,N-ditetradecylacetamide Other Lipids: (provide structural integrity of the nanoparticles) • 1,2-distearoyl-sn-glycero-3phosphocholine • cholesterol Salts: (these help maintain the PH of the vaccine)
• sodium acetate • tromethamine • tromethamine hydrochloride Other: • sucrose (protects the nanoparticles when prozen)
• bibasic sodium phosphate dihydrate • monobasic potassium phosphate • potassium chloride • sodium chloride Other: • water for injection
O u r L a n d . O u r C u l t u r e . O u r F u t u r e .
Made with FlippingBook - professional solution for displaying marketing and sales documents online